Overview
- Emcure cut Poviztra’s starting dose to ₹3,999 per month, with average reductions of 47% on higher strengths and the 2.4 mg dose now ₹8,999, a move the company says will widen access.
- Poviztra is Novo Nordisk’s semaglutide for weight management that Emcure sells under its own brand in a once‑weekly pen available in five doses.
- The reductions come after semaglutide’s India patent expired, as local firms launched generics priced 50% to 80% below the original versions.
- Novo Nordisk also lowered prices on Wegovy by about 48% and on Ozempic by 36%, signaling a broader reset in this fast‑growing drug class.
- The government cautioned against unsupervised use of GLP‑1 drugs such as semaglutide, noting side effects that range from nausea and vomiting to pancreatitis, kidney injury and bowel obstruction.